Trial Profile

Phase 1 single ascending dose study of ARGX-113 in healthy volunteers

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 29 Sep 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Efgartigimod alfa (Primary)
Indications Myasthenia gravis
Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics

Most Recent Events

25 Aug 2016 According to an arGEN-X media release, complete data set from the study will be presented at argenx R&D day, 22 September 2016.
09 Jan 2016 New trial record
05 Jan 2016 According to an arGEN-X media release, the dose-escalation part of this study has been completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com